Kyntheum (Brodalumab)

Brodalumab binds to the interleukin‑17 receptor A (IL‑17RA) on immune and skin cells, blocking the activity of several IL‑17 cytokines. This interruption prevents downstream inflammatory signaling that drives the development of psoriatic skin lesions.

The dosing regimen for Kyntheum is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response. The prescriber will provide the specific injection schedule and any necessary adjustments.

Safety of brodalumab in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant.

To request Kyntheum, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

Kyntheum (brodalumab) blocks the IL‑17 receptor, whereas other approved agents such as secukinumab and ixekizumab target the IL‑17A cytokine itself. All three reduce psoriatic inflammation, but differences in receptor versus cytokine blockade may influence efficacy, dosing frequency and safety profiles, which are evaluated by the treating physician.

Kyntheum must be stored in a refrigerator at 2 °C to 8 °C. Keep the product in its original carton, protect it from light, and do not freeze or shake the vial. Once removed from refrigeration, it may be used for a limited period as indicated in the product labeling.

Kyntheum is given by subcutaneous injection. The injection can be performed by a healthcare professional or, after appropriate training, by the patient or caregiver using the pre‑filled syringe or autoinjector provided with the product.

The most serious risks include the emergence of suicidal thoughts or behaviors, severe or opportunistic infections, and potentially life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely for any new psychiatric symptoms or signs of infection.

Kyntheum should not be used in individuals with known hypersensitivity to brodalumab or any of its excipients, in patients with active serious infections, or in those who are pregnant or breastfeeding unless the benefit outweighs the risk. Caution is also advised for patients with a history of depression or suicidal ideation.